Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.49 |
| ▸ | MGLL | Q99685 | 4/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18286056 | 0.82 | KIF11 (0.50) | HSD11B1MGLLPDK2 | |
| SCHEMBL6678525 | 0.79 | KMO (0.59) | HSD11B1MGLLKMO | |
| SCHEMBL4671351 | 0.79 | HSD11B1 (0.59) | HSD11B1NOTUMMGLLKDR | |
| SCHEMBL16505883 | 0.79 | KMO (0.68) | HSD11B1NOTUMKMO | |
| SCHEMBL16506324 | 0.78 | HSD11B1 (0.50) | HSD11B1MGLL | |
| SCHEMBL24400223 | 0.78 | KMO (0.43) | NOTUMKDRKMO | |
| SCHEMBL1920001 | 0.78 | TSHR (0.59) | NOTUMPDK2KDRKMO | |
| SCHEMBL9526608 | 0.78 | NOTUM (0.46) | NOTUMKDRKMO | |
| SCHEMBL29624981 | 0.78 | TSHR (0.59) | NOTUMPDK2KDRKMO | |
| SCHEMBL30255650 | 0.78 | NOTUM (0.46) | NOTUMKDRKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222838-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2018-08-09 | — | — | US | disclosed |
| US-9822058-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20150057238-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057238-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, AADAT | HSD11B1 381/4885NOTUM 527/4885MGLL 936/4885 |
| US-20180222838-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, AADAT | HSD11B1 381/4885NOTUM 527/4885MGLL 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.